<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2008-03-19" updated="2019-12-02">
  <drugbank-id primary="true">DB06365</drugbank-id>
  <name>Sapacitabine</name>
  <description/>
  <cas-number>151823-14-2</cas-number>
  <unii>W335P73C3L</unii>
  <average-mass>490.645</average-mass>
  <monoisotopic-mass>490.315520468</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in solid tumors, cutaneous t-cell lymphoma, myelodysplastic syndrome, and leukemia (lymphoid).</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Sapacitabine appears to act through a dual mechanism. It interferes with DNA synthesis by causing single-strand DNA breaks and also induces arrest of cell cycle progression mainly at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite or a substance into which the drugs converts after ingestion by patients, have demonstrated potent anti-tumor activity in preclinical studies.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.</description>
    <direct-parent>Pyrimidine 2'-deoxyribonucleosides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Nucleosides, nucleotides, and analogues</superclass>
    <class>Pyrimidine nucleosides</class>
    <subclass>Pyrimidine 2'-deoxyribonucleosides</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Fatty amides</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydropyrimidines</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>N-arylamides</alternative-parent>
    <alternative-parent>Nitriles</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Pyrimidones</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tetrahydrofurans</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carbonitrile</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty amide</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydropyrimidine</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>N-arylamide</substituent>
    <substituent>Nitrile</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Pyrimidine 2'-deoxyribonucleoside</substituent>
    <substituent>Pyrimidone</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tetrahydrofuran</substituent>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Glycosides</category>
      <mesh-id>D006027</mesh-id>
    </category>
    <category>
      <category>Nucleic Acids, Nucleotides, and Nucleosides</category>
      <mesh-id>D009706</mesh-id>
    </category>
    <category>
      <category>Nucleosides</category>
      <mesh-id>D009705</mesh-id>
    </category>
    <category>
      <category>Pyrimidines</category>
      <mesh-id>D011743</mesh-id>
    </category>
    <category>
      <category>Pyrimidinones</category>
      <mesh-id>D011744</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sapacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sapacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Sapacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sapacitabine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.83</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>9.15e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N-{1-[(2R,3S,4S,5R)-3-cyano-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}hexadecanamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>sapacitabine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>490.645</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>490.315520468</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1C#N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C26H42N4O5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C26H42N4O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-23(32)28-22-16-17-30(26(34)29-22)25-20(18-27)24(33)21(19-31)35-25/h16-17,20-21,24-25,31,33H,2-15,19H2,1H3,(H,28,29,32,34)/t20-,21+,24-,25+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LBGFKUUHOPIEMA-PEARBKPGSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>135.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>132.29</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>56.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>11.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-1.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>135703</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sapacitabine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2105681</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>